Anticalin Proteins in Immuno-Oncology
Antibody-Anticalin multispecific fusion proteins can be used to pursue several innovative approaches in immuno-oncology, particularly when addressing the “immune synapse” between immune cells and cancer cells. One example is to drive an efficient activation of tumor-specific T cells within the vicinity of the tumors, the space called the tumor microenvironment, thereby avoiding some of the toxicity observed with peripheral T cell activation in healthy tissues. Pieris is committed to becoming a leader in developing tumor-localized T cell costimulatory agonists, led by its wholly owned lead candidate, PRS-343.
Additionally, Pieris has immuno-oncology collaborations with Servier and Seattle Genetics.